Autres langues Ionis Pharmaceuticals, Inc.

Actions

IONS

US4622221004

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 12/06/2026			Varia. 5j.	Varia. 1 janv.
73,28 ^USD	-0,74%		-1,62%	-7,38%

12/06	Ionis Pharmaceuticals publie de nouvelles données positives de l'étude CORE-OLE évaluant l'olezarsen dans l'hypertriglycéridémie sévère	CI
10/06	Transcript : Ionis Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 08:40 AM

Autres langues

12/06	Ionis Pharmaceuticals Shares Positive New Data From Core-Ole Study Evaluating Olezarsen In Severe Hypertriglyceridemia
08/06	Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
08/06	Ionis Pharmaceuticals, Inc. Announces Appointment of Ludwig Hantson, Ph.D. to Board of Directors, Effective June 8, 2026
05/06	Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia at upcoming congresses
04/06	Biogen Gets FDA Breakthrough Designation for Spinraza Successor Salanersen
04/06	Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
03/06	Ionis Pharmaceuticals Insider Sold Shares Worth $605,360, According to a Recent SEC Filing
28/05	GSK Says Hepatitis B Drug Cured One Fifth of Patients in Late-Stage Trials -- Update
28/05	GSK erzielt teilweisen Therapieerfolg mit Hepatitis-B-Wirkstoff
28/05	GSK Says Hepatitis B Drug Candidate Cured Some Patients in Late-Stage Trials
28/05	Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
28/05	Ionis Pharmaceuticals Announces Positive Pivotal Data for Bepirovirsen in Chronic Hepatitis B
27/05	Health Care Up as Traders Hedge on Outlook - Health Care Roundup
14/05	Ionis Pharmaceuticals Announces Topline Results from Phase 2 Celia Study of Diranersen
14/05	Ionis partner Biogen announces topline results from phase 2 Celia study of diranersen
14/05	Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
04/05	Ionis to host 2026 virtual Annual Meeting of Stockholders
01/05	Ionis to present at upcoming investor conferences
29/04	Ionis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
29/04	Ionis Pharmaceuticals Q1 Net Loss Narrows, Revenue Increases; Lifts 2026 Revenue Guidance
29/04	Ionis Pharmaceuticals : Q1 2026 Ionis Earnings Slides
29/04	(IONS) Ionis Pharmaceuticals Expects 2026 Total Revenue Range $875M - $900M, vs. FactSet Est of $808.5M
29/04	Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q1 Loss $0.56 a Share, vs. FactSet Est of $0.88 Loss
29/04	Earnings Flash (IONS) Ionis Pharmaceuticals, Inc. Reports Q1 Revenue $246.0M, vs. FactSet Est of $195.6M
29/04	Ionis Pharmaceuticals: Q1 Earnings Snapshot